The FGF2-binding peptide P7 inhibits melanoma growth in vitro and in vivo

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 8, 2012, Pages 1321-1328

  Yu, Yonglin ^a   Gao, Susu ^a   Li, Quchou ^a   Wang, Cong ^b   Lai, Xinqiang ^a   Chen, Xilei ^a   Wang, Ruixue ^a   Di, Jingfang ^a   Li, Tao ^a   Wang, Wenhui ^a   Wu, Xiaoping ^a,b  

^a JINAN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; FGF2 binding peptide; Melanoma; Proliferation

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR 2; GLUTAMYLLEUCYLGLYCYLPROLYLGLYCYLLEUCYLALANYLSERYLLEUCYLGLYCYLTHREONINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROLYLPROLYLLEUCYLGLUTAMYLALANYLTHREONYLLEUCYLGLYCYLGLYCYLGLYCYLSERINE; PROTEIN BCL 2; PROTEIN KINASE B; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; FEMALE; FIBROBLAST GROWTH FACTOR 2; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR BURDEN;

EID: 84864352973     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1201-7     Document Type: Article

References (22)

1. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8(3):235-253. doi:10.1038/nrd2792
2. Bonnet H, Filhol O, Truchet I, Brethenou P, Cochet C, Amalric F, Bouche G (1996) Fibroblast growth factor-2 binds to the regulatory beta subunit of CK2 and directly stimulates CK2 activity toward nucleolin. J Biol Chem 271(40):24781-24787 (Pubitemid 26333225)
3. Bossard C, Laurell H, Van den Berghe L, Meunier S, Zanibellato C, Prats H (2003) Translokin is an intracellular mediator of FGF-2 trafficking. Nat Cell Biol 5(5):433-439. doi:10.1038/ncb979 (Pubitemid 36592266)
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein- dye binding. Anal Biochem 72:248-254. doi:10.1006/abio. 1976.9999
5. Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M (2003) Fibroblast growth factors and their receptors in urological cancers: Basic research and clinical implications. Eur Urol 43(3):309-319. doi:10.1016/s0302- 2838(03)00005-8 (Pubitemid 36314245)
6. Dailey L, Ambrosetti D, Mansukhani A, Basilico C (2005) Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 16(2):233-247. doi:10.1016/j.cytogfr. 2005.01.007 (Pubitemid 40616120)
7. Facchiano A, Russo K, Facchiano AM, De Marchis F, Facchiano F, Ribatti D, Aguzzi MS, Capogrossi MC (2003) Identification of a novel domain of Wbroblast growth factor 2 controlling its angiogenic properties. J Biol Chem 278(10):8751-8760. doi:10.1074/ jbc.M209936200 (Pubitemid 36800632)
8. Korc M, Friesel RE (2009) The role of Wbroblast growth factors in tumor growth. Curr Cancer Drug Targets 9(5):639-651
9. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T, Kato Y, Nitta A, Arimoto Y, Kondo Y (1995) Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 72(2):319-323. doi:10.1038/bjc.1995.331
10. Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, Berking C, Moller H, Maczey E, Rassner G, Herlyn M, Garbe C (2003) Fibroblast growth factor-2 but not Mel-CAM and/or beta 3 integrin promotes progression of melanocytes to melanoma. Exp Dermatol 12(3):296-306. doi:10.1034/j.1600-0625.2003.120310.x (Pubitemid 36934717)
11. Neary JT, Kang Y, Shi Y-F (2005) Cell cycle regulation of astrocytes by extracellular nucleotides and Wbroblast growth factor-2. Purinergic Signal 1(4):329-336. doi:10.1007/s11302-005-8075-y (Pubitemid 43019533)
12. Park SJ, Kim SH, Choi HS, Rhee Y, Lim S-K (2009) Fibroblast growth factor 2-induced cytoplasmic asparaginyl-tRNA synthetase promotes survival of osteoblasts by regulating anti-apoptotic PI3 K/ Akt signaling. Bone 45(5):994-1003. doi:10.1016/j.bone. 2009.07.018
13. Ribatti D, Vacca A, Ria R, Marzullo A, Nico B, Filotico R, Roncali L, Dammacco F (2003) Neovascularisation, expression of Wbroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer 39(5):666-674. doi:10.1016/s0959- 8049(02)00150-8 (Pubitemid 36287380)
14. Shoo BA, Kashani-Sabet M (2009) Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg 28(2):96-102. doi:10.1016/j.sder.2009.04.005
15. Sorensen V, Nilsen T, Wiedlocha A (2006) Functional diversity of FGF-2 isoforms by intracellular sorting. BioEssays 28(5):504-514. doi:10.1002/bies. 20405 (Pubitemid 43668065)
16. Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM (1999) Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine. Cancer Res 59(19):4919-4926 (Pubitemid 29472897)
17. Tsunoda S, Nakamura T, Sakurai H, Saiki I (2007) Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci 98(4):541-548. doi:10.1111/j.1349-7006.2007. 00432.x (Pubitemid 46562745)
18. Umemoto M, Yokoyama Y, Sato S, Tsuchida S, Al-Mulla F, Saito Y (2001) Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. Br J Cancer 85(7):1032-1036. doi:10.1054/bjoc.2001.2034 (Pubitemid 33016006)
19. Wang C, Lin S, Nie Y, Jia X, Wang J, Xiao J, Wu J, Li X, Wu X (2010) Mechanism of antitumor effect of a novel bFGF binding peptide on human colon cancer cells. Cancer Sci 101(5):1212-1218. doi:10.1111/j.1349-7006.2010.01501.x
20. Wu X, Yan Q, Huang Y, Huang H, Su Z, Xiao J, Zeng Y, Wang Y, Nie C, Yang Y, Li X (2010) Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J Cell Mol Med 14(1-2):351-356. doi:10.1111/j.1582- 4934.2008.00506.x
21. Wu X, Jia X, Ji Y, Wang C, Yu Y, Gao S, Li Q, Li X (2011) EVects of a synthetic bFGF antagonist peptide on the proteome of 3T3 cells stimulated with bFGF. Int J Pept Res Ther 17(1):53-59. doi:10.1007/s10989-011-9240-5
22. Zhou HL, Li XM, Meinkoth J, Pittman RN (2000) Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol 151(3):483-494. doi:10.1083/jcb.151.3.483